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Abstract

COST-EFFECTIVENESS ANALYSIS OF TUNNELED CENTRAL VENOUS
CATHETER DRESSINGS IN CANADIAN BLOOD STEM CELL TRANSPLANT
Melanie Keeler
Dissertation Chair: Barbara K. Haas, Ph.D.
The University of Texas at Tyler
May 2014
Central venous catheters (CVC) are integral tools used in blood stem cell transplant with
registered nurses responsible for maintenance and catheter care. However, CVC practice
guidelines in the literature are inconsistent or absent. Gaps in the evidence generated
several research questions regarding potential variability in CVC practice across Canada
and the impact that variability may have on healthcare spending and patient outcomes. A
survey revealed differences in CVC practice across Canada that coincide with discrepant
and/or absent guidelines. Current cost-analyses within the blood stem cell transplant
population were also absent in the literature. The cost of a single CRBSI was estimated
using a case controlled comparison of records. The study quantified how costs can be
contained through prevention efforts, and identified the importance of nursing research
targeting infection control. One prevention area was tested in terms of infection

i

outcomes with tunneled catheters used by blood stem cell transplant recipients. The
descriptive study compared three different nursing strategies for CVC exit site care in
terms of CRBSI and cost. Results indicated each strategy poses similar CRBSI risks with
significant differences in expense. Maximum value was attributed to transparent
dressings followed by removing the dressing and lastly using a gauze dressing. The no
dressing strategy was a more cost-effective alternative when a transparent dressing
cannot be tolerated. Further analysis of the data generated in this project is ongoing with
the intent to delineate other areas of nursing influence on CRBSI and identify further
potential areas for cost containment.
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Chapter One: Introduction
Mature cells in the human body stem or originate from a parent cell. The first cell
in a lineage of cell chains that differentiate until maturity is often defined as a stem cell.
There are many types of stem cells throughout the body that are the focus of transplant
research. Hematopoietic or CD34 stem cells are sourced in the bone marrow and
responsible for the production of several cell chains that eventually develop into the
blood supply (Tomblyn et al., 2009). Certain hematological disorders interfere with
normal blood and marrow functioning which may require a blood stem cell transplant.
The basics of blood stem cell transplant are to eliminate abnormal cells and introduce a
new source for healthy blood production. The source of stem cells used for transplant has
given rise to different terms and medical acronyms. Transplanted stem cells may be
given within a volume of bone marrow, otherwise known as a bone marrow transplant
(BMT). Hematopoietic progenitor cell transplant (HPCT) uses isolated stem cells that
are filtered from the bloodstream of the donor through a process known as apheresis. A
cord transplant uses stem cells collected from a donated umbilical cord. BMT, HPCT,
and cord transplant are all subcategories of the broader blood stem cell transplant (SCT)
population.
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Scientific progress, albeit beneficial, has increased hospital patient acuity outside
of Intensive Care Units. Registered nursing care with acute populations often requires
advanced competency training. Blood stem cell transplant nurses possess specialty
knowledge for delivering treatments such as chemotherapy, blood products, and
biologicals etc. These nurses must also develop skillful assessment abilities for
monitoring critically ill patients, managing symptoms, and alleviating side effects of
treatment. Complications faced by blood stem cell transplant recipients include weight
loss, nausea, and graft versus host disease; however, infection predominates, occurring in
over 60% of patients (Weissinger et al., 2011). Infection during acute transplant and
beyond increases reliance on registered nursing care as several behaviors, actions,
interventions, and facilitation of the multidisciplinary team are needed to address
occurrence.
Central venous catheters (CVC) are an integral part of blood stem cell transplant
nursing and a potential source of infection. Removing the dressing from the healed exit
site of a tunneled CVC is a recent trend in the industry. In clinical practice, this author
has observed the implementation of policy changes such as dressing removal with little
explanation or provision of supporting evidence. Westbrook, Duffield, Li, and Creswick
et al. (2011) point out that registered nurses work in such a high paced environment that
they only spend around 37% of their time with patients. Majid et al. (2011) report that
registered nurses in Singapore claim they are unable to keep up to date with current
evidence due to heavy workloads. Findings suggest staff nurses entrust nurse leaders to
expedite the dissemination of evidence that is incorporated at the bedside. Questionable
policy changes may foster slow change or even initial non-adherence as was observed in
2

personal practice. Whether the dressing on a healed tunneled CVC exit site should be
removed or maintained depends on the standpoint of the consulting panel. (Gillies,
O’Rordan, Sheriff, & Rickard, 2011; Infusion Nurses Society, 2011; O’Grady et al.,
2011; Olsin et al., 2004; Scales, 2010b; Seiler & Pember, 2012; Toshiyuki et al. 2012).
Gaps in the evidence coupled with recent changes mandating dressing removal at the
authors clinical practice site generated the research questions for this project.
Canada does not have universal practice standards for CVC nursing care.
Initially, it was unclear if removing the dressing from a healed tunneled CVC exit site
was becoming a baseline nationwide care strategy. Boersma and Schouten (2010)
reported that care differences occur in elements of CVC care when there are unclear
positions on the best course of action. It was hypothesized that CVC practice in blood
stem cell transplant also differs across Canada which may result in excess healthcare
spending and different outcomes. Subsequently, a descriptive survey of Canadian
practice was planned and conducted in the summer of 2013 (Appendix A) following
university institutional review board (IRB) approval (Appendix B). This initial survey,
reported in Chapter Two, notes similar findings to Boersma and Schouten (2010)
revealing differences in CVC practice across the nation that coincide with discrepant
and/or absent CVC guidelines. Results of the study are currently in press according to
the author guidelines in Appendix C, and publisher permission to include the manuscript
in this portfolio was granted (Appendix D).
Following the initial survey study, it was unclear if CVC care differences pose the
same risks for negative outcomes. Device-associated complications such as catheterrelated bloodstream infection (CRBSI) are costly and avoidable. The literature did not
3

contain Canadian estimates of CRBSI costs beyond one study that only considered fees
for extended length of hospital stay (Raschka, Dempster, & Bryce 2013). The unique
needs of the blood stem cell transplant population and use of one specific type of CVC
among 90% of centers surveyed in the first study directed research attention to the need
to determine the cost of a single CRBSI alongside a planned study comparing negative
outcomes among CVC dressing strategies. Understanding costs associated with the
different dressing strategies was an integral first step to determining if one particular
strategy was more effective in terms of preventing infection and the cost effectiveness
associated with the various dressing strategies. University IRB and ethics board approval
from the practice site (Appendix B) were secured for implementing a two-pronged study
to examine costs associated with CRBSI and to determine the incidence of CRBSI among
patients whose CVC sites were maintained using one of three dressing strategies.
The cost of a single CRBSI was estimated using a case controlled comparison of
records and is reported in Chapter Three. Study results quantified CRBSI in Canadian
dollars, thus informing how costs can be contained through prevention efforts and
identifying the importance of nursing research targeting infection control. Concomitant
examination of CRBSI with different exit site dressings was compared as planned.
Asepsis theory guided variable selection (Duval, 2010). Tenets of the theory portray coexistence versus pathological relationships between hosts and micro-organisms that can
be influenced by clinical actions. The descriptive study compared three different nursing
strategies for CVC exit site care (transparent dressing, no dressing, or gauze dressing) in
terms of CRBSI and fees for supplies. Results from this study are reported in Chapter
Four.
4

Findings from this emerging program of research have the potential to influence
blood stem cell transplant nursing practice in Canada and across the globe. These studies
provide empirical data to help clinicians make informed and evidence-based practice
decisions that may lead to improved patient outcomes and responsible fiscal practices.
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Chapter Two: Central Line Practice in Canadian Blood and Marrow Transplant

Abstract and manuscript prepared for the Canadian Oncology Nursing Journal (in
Press)
Abstract
More than 800 blood cell and bone marrow transplants are performed annually
in Canada to treat fatal cancers and rare blood disorders. Central vascular
access is fundamental in blood and marrow transplant nursing to facilitate
chemotherapy and blood product infusions. A tunneled Central Venous
Catheter (CVC) is the vascular access device-of-choice in the cell and
marrow transplant population. Several practice guidelines direct nursing
policy and procedure for CVC management and care. CVC insertion and
removal guide- lines are increasingly relevant given the widening scope of
advanced practice nursing. Unresolved issues are noted among the most
heavily cited CVC practice recommendations accessible via the Centers for
Disease Control and Prevention (CDC). A descriptive survey based on the
CDC guidelines was conducted to identify potential variability in CVC
strategies in Canadian blood and marrow transplant nursing. Survey results
indicate nationwide differences in catheter site selection, educational
strategies, dressing strategies, delegation of dressing changes, and volumes
6

of flushing and locking solutions used to manage catheter patency.
Variability in practice coincides with gaps in the evidence identified in
practice recommendations. Future studies comparing specific care approaches
to device-associated complications are needed to resolve issues and strengthen
practice guidelines.

7

Chapter Two: Central Line Practice in Canadian Blood and Marrow Transplant
Blood cell and/or bone marrow transplant is conducted for certain lifethreatening diseases and blood cancers. Transplant involves obliterating the
bone marrow followed by repopulation with donated cells. Tomblyn et al.
(2009) explain that disease is both targeted and eradicated by proxy through
destroying the system of origin. The curative aim of treatment is for
transplanted donor cells to manufacture a new disease-free blood supply within
the recipient. Procedurally, blood and bone marrow transplant is provided
through intravenous infusions of chemotherapy, supportive medications, fluids,
and transfusions of blood products including donor cells. A central venous
catheter (CVC) is one type of vascular access device that was specially
developed for complex medical care by enabling long term use, exchange of
large fluid volumes, and delivery of medications caustic to peripheral veins
(Scales, 2010). Patients describe a CVC as instrumental towards cure because it
is the portal for delivering treatment (Møller & Adamsen, 2010).
CVC care and management, as well as patient education, are
primarily the responsibility of registered nurses in Canada. Given that risks
are associated with using medical devices patient safety is a central concern.
Pneumothorax, infection, and thrombosis are examples of complications
associated with CVC use (Kim et al., 2010; O’Grady et al., 2011). Infection
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is of particular concern with the cell transplant population given their
weakened immunity from disease and treatment (Tomblyn et al., 2009).
Nursing policy and procedures routinely incorporate study findings that
correlate CVC care strategies with minimized risks. However, at present,
there remain gaps in the evidence to support nursing practice in this area.
Boersma and Schouten (2010) found that actual CVC practices vary across
Europe as a manifestation of discrepant and/or absent practice guidelines. It
is not known what the adherence to guidelines regarding CVC care is across
Canada.
Several jurisdictions provide clinical practice guidelines for CVC
competency including insertion, routine care, maintenance, and removal
(Appendix A). The recommendations by O’Grady et al. (2011) are the most
frequently cited in North America given open access via the American Centers
for Disease Control and Prevention (CDC) and collaboration with several
expert panels. Unresolved issues noted by O’Grady et al. (2011) point out gaps
in the evidence concerning CVC care and management worth future research
attention. Specific issues in blood and marrow transplant nursing described in
the report are that no evidence-based recommendations can be made for optimal
site selection for the catheter, optimal dressing type, removing the dressing
from a healed tunneled CVC site, or managing catheter patency. Periodic
competency training is also encouraged with no clear stance on frequency.
Policy makers and Registered Nurses are faced with distinguishing between
conflicting recommendations and using practice-based approaches when
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evidence is lacking. The purpose of this descriptive study was to examine
adherence to recommended CVC guidelines within the Canadian blood and
marrow transplant population and identify potential nationwide variability in
care strategies to be tested in future research.
Method
The study was approved by the institutional review board at the
University of Texas at Tyler. As no other instrument existed, a descriptive
survey was created for the purposes of this study, based on infection prevention
guidelines for intravascular catheters by O’Grady et al. (2011). The survey
included 33 questions of inquiry in four areas related to the tunneled CVC
commonly used in blood and marrow transplant: insertion, routine care,
maintenance, and removal. Survey questions contained various response
options: yes or no choices, multiple choice, and open-ended formats. The survey
was electronically distributed to 25 centres within the 14 blood cell and bone
marrow transplant programs across Canada. A purposive sample of advanced
practice nurses, nurse educators, managers, and program coordinators in blood
and marrow transplant was invited to voluntarily answer questions regarding the
CVC policy at their centre. One response per centre was accepted. A draw for a
$50 gift card was used as an incentive for participation.
Results and Interpretation
Thirteen respondents returned surveys and indicated provision of blood
cell and/or bone marrow transplant at their centre (Appendix B). Three
surveys were omitted from the analysis, as only the first two demographic
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questions were answered, for a total response rate of 40% (n=10). Responses
included in the analysis represent both inpatient and outpatient settings treating
adult (70%) and pediatric (40%) patients, seven of eight provinces offering
blood and marrow transplant, and approximately 67% of the Canadian blood and
marrow transplant population (Canadian Blood and Marrow Transplant Group,
2013).
The survey results reveal that variations in CVC practice coincide with
discrepant and/or absent guidelines in the areas of competency training,
insertion, routine care, maintenance, and removal. CVC practice is reported as
the duty of physicians and nurses with overlapping responsibility for insertion,
dressing changes, and removal. Forty per cent of centres indicated that CVC
care is also delegated to patients, family members, and lay caregivers.
Competency in CVC care requires learning skills, the rationale for device use,
and how to avoid complications. Studies recommend targeted education to
maintain vigilance with care and avoid human error (Faruqi et al., 2012;
Rosenthal, 2009). All survey respondents reported that their centre has a policy
in place to educate staff on insertion, routine care, and maintenance of a CVC.
All centres that delegate routine care reported having a policy in place for
educating patients, families, and lay caregivers. Sixty per cent of centres repeat
CVC education annually while the remaining centres only rein- force policy
changes. Different educational strategies coincide with the subjective
recommendation by O’Grady et al. (2011) to periodically evaluate knowledge and
concordance with recommended guidelines.
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Insertion
Survey responses indicate CVC insertion is a physician responsibility in
the majority of cases and adherence is fully observed in avoiding prophylactic
antibiotics, avoiding femoral veins, and using tunneled or implanted catheters.
Only one centre (10%) reported the use of antimicrobial impregnated cuffs
which O’Grady et al. (2011) claim is only necessary with persistent infection
in spite of prevention efforts. Instead, it is advised to employ multiple infection
prevention strategies, known as bundling. CVC insertion bundling consists of:
proper hand hygiene, using maximum barrier precautions (sterile gown, drape,
gloves, equipment, and wearing a mask), using a >.5% chlorhexidine skin prep
solution, choosing the appropriate site if known, and daily review of the
necessity of the catheter with prompt removal when no longer essential (Faruqi
et al., 2012; Moreau, 2009). Supervision for inexperienced practitioners and use
of ultrasound guidance is also recommended to reduce the risk of insertionrelated complications (Shekelle et al., 2013). In the survey results, adherence to
bundling insertion strategies and use of ultrasound guidance was unknown by
the responding nurses. Of note, the procedure is out of nursing practice scope in
the majority of settings. The reported variation regarding insertion site selection
coincides with the lack of evidence supporting subclavian over intra jugular
sites, or one side of the body over the other (Ge et al., 2012). Awareness of
insertion guidelines is increasingly important given advanced practice nurses
are beginning to engage in line placement (10%).
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Routine Care and Maintenance
There is general consensus in the literature that a newly inserted CVC
is covered with a dressing, not submerged in water, and has an extra covering
for showering. However, the optimal dressing material to use remains unclear
(Gillies, O’Riordan, Sheriff, & Rickard, 2011). There is also consensus in the
literature on the type of skin antiseptic to be used (>0.5% chlorhexidine or 70%
alcohol, tincture of iodine, or iodophor for infants or allergies) and frequency
of gauze or transparent dressing changes at 48 hours or after seven days
respectively (Infusion Nurses Society, 2011; O’Grady et al., 2011; Scales,
2011). All centres surveyed reported full adherence to recommendations
specific to gauze or transparent materials and use of barriers and aseptic
techniques for line care. However, 20% reported no additional protection is
used for showering. Non-adherence to the recommendation may be due to the
waterproof capability of a transparent dressing, which is the most commonly
used material (90%) to cover a CVC exit site. Case studies report the
elimination of water-borne bloodstream infection when using a waterproof
covering for hygiene, even when a dressing is used on a CVC exit site, as the
strategy provides added protection against colonization of caps and
connections from tap water (Baird et al., 2011; Toscano et al., 2009).
Another variation in practice across Canada coincides with the discrepancy
in views about maintaining or removing the dressing from a healed tunneled exit
site. The most recent Cochrane meta-analysis comparing dressing materials
reported no study designed to draw comparisons with a “no dressing” group
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(Gillies et al., 2011). Forty per cent of the centres surveyed in this study reported
that healed tunnel sites are left open to air. The 2011 guidelines from the
Infusion Nurses Society (INS) cite only one study supporting the no-dressing
recommendation while the CDC remains irresolute on the issue.
Links between the inflammatory and coagulation response in the
bloodstream interrelate infection and thrombosis (Levi, van der Poll, & Schultz,
2012). The correlation of cumulative infection and thrombotic risks in cancer
patients with a CVC highlights the importance of prevention strategies (Hitz et
al., 2012; Rowan et al., 2013). All centres reported CVC patency is maintained
with normal saline flushing and heparin locking, though no centre used the
same combinations or volumes. The INS (2011) defers maintenance decisions to
instructions by product suppliers. Camp-Sorrell (2010) notes manufacturer
recommendations continue to dictate care without providing current supportive
evidence of product effectiveness versus complications. Varying volume and
concentration types of locking solutions across Canada speak to the lack of
guidance for preventing catheter occlusion which may, in turn, influence
infection rates. Dibb et al. (2012) agree that maintaining the integrity of a CVC
through the use of anti-coagulants and antimicrobial locking solutions may be a
feasible approach to preserving central access while admitting more evidence is
needed. All respondents in this study reported that attempts are made to
salvage sluggish and/or occluded lines with anti-coagulants, and 60% indicated
the use of anti-infective locking solutions are options for managing known
infections. Practice guidelines for preventing infection do not speak to
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thrombotic correlations, do not advise anticoagulant use for the purpose of
preventing catheter-related bloodstream infection, and caution against use of
anti-infective locking solutions unless repeat infections are problematic
(O’Grady et al., 2011). Sodium citrate is one suggested multipurpose locking
solution approved for use in Canada, though no centre in this survey reported
use of the product (O’Grady et al., 2011).
Removal
Catheter-related infection, malfunction, or total occlusion may necessitate
early line removal or replacement. Similar to insertion, CVC removal was
reported in this study as primarily a physician responsibility with delegation to
nurses in 20% of situations. Line removal is not recommended based on fever
alone but is consistently advised for unnecessary catheters (INS, 2011; O’Grady
et al., 2011; Tomblyn et al., 2009). Twenty per cent of the centres do not adhere
to prompt removal however results may be limited to the subjective interpretation
of necessity by the nurses surveyed.
Discussion
The results of a descriptive survey of Canadian CVC practice support
similar findings in Denmark and the Netherlands by Boersma and Schouten
(2010). When issues concerning CVC care remain unresolved in the literature,
it poses clinical dilemmas for clinicians. Practice-based decisions often guide
CVC care approaches when evidence is lacking or discrepant. Practice
guidelines are not provided with the intent to replace clinical judgment rather
they serve to narrow variability when there is convincing evidence supporting
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certain care strategies over alternatives. Adherence to resolute guidelines
depends on awareness of disseminated findings and time needed to incorporate
findings into practice. Program accreditation is one option for ensuring
minimum care standards within certain treatment areas. Regimented
competency training may also ensure that diligence is maintained in practice.
Care standards can only assist in mitigating risks when sufficient data are
available. Gaps in the evidence may lead to different care approaches being
adopted that may result in differences in clinical effectiveness. Strengthening
evidence through research is still needed in several aspects of CVC practice.
The plethora of available central venous access devices and variation in
patient requirements for care points to the need for population-centred
inquiries. Camp-Sorell (2010) notes that best practice is often identified
through measuring systematic practices against outcomes. Studies comparing
different CVC care approaches to infection and thrombosis rates may
provide pragmatic resolutions to existing practice discrepancies. Measuring
overlapping constructs contributes to a bank of insufficient findings that are
often excluded from meta-analysis (Ge et al., 2012). Examining specific
vascular access devices within specific clinical populations should be
considered for controlling construct validity. Variable practice and
unresolved issues for recommendations point to the need for future dressing
studies with tunneled CVCs, including comparisons to a “no-dressing”
group. Mathers (2011) notes the absence of standard flushing protocols for
central access across America, which coincides with these survey results of
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Canadian practice. Empirical studies testing the effectiveness of particular
flushing and locking solutions with specific devices in specific populations
are needed for the development of practice guidelines.
Conclusion
Medical advances have allowed complex treatment for uncommon
diseases. Central vascular access devices are commonplace in specialty areas
treating acutely ill patients. Registered and Advanced Practice Nurses are in a
position of positively influencing the incidence of complications with medical
devices. Incongruent practice advice and gaps in evidence manifest in different
care approaches worth research attention as variable practice may inadvertently
propel disparate care. Results from the descriptive study of CVC practice
across Canada indicate some centres do not fully adhere to all recommendations
and that variable care approaches coincide with discrepant advice and gaps in
evidence. Studies focusing on preventing catheter-related occlusions and
infections have the potential to increase care quality. Incorporating the study of
the cancer system capacity when investigating practice comparisons may,
provide additional validation of nursing influence.
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Appendix A

Location
Australia

Canada

Europe

Global

Japan

Table1
Recommendations for CVC Practice
Advisory
Access
Australian Society for
www.healthinfonet.ecu.edu.au
Parenteral and Enteral
Nutrition (AuSPEN)
Center for Health Care
www.health.qld.gov.au/chrisp
Related Infection
Surveillance and Prevention
(CHRISP)
Australian Commission on
www.health.qld.gov.au
Safety and
Quality in Health Care,
National Safety
and Quality Health Service
Standard
BC Cancer Agency
www.bccancer.bc.ca
Canadian Patient Safety
www.saferhealthcarenow.ca
Institute (CPSI)
Public Health Agency of
www.phac-aspc.gc.ca
Canada: Canadian
Nosocomial Infection
Surveillance Program
(CNISP)
Registered Nursing
rnao.ca
Association of Ontario
(RNAO)
European Center for
ecdc.europa.eu
Disease Prevention (ECDC)
European Society for
www.espen.org
Clinical Nutrition and
Metabolism (ESPEN)
International Federation of
www.theific.org
Infection Control (IFIC)
World Health Organization www.who.int/csr/resources/publications/dru
gresist/en/whocdscsreph200212.pdf
Ministry of Health, Labour, www.mhlw.go.jp/english/index.html
and Welfare
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New
Zealand
United
Kingdom

United
States

Intravenous Nursing New
Zealand (IVNNZ)
British Committee for
Standards in Hematology
(BCSH)
National Institute for
Clinical Excellence (NICE)
Royal College of Nursing
American Society of
Critical Care
Anesthesiologists (SOCCA)
Center for Disease Control
and Prevention (CDC)
Infectious Disease Society
of America (IDSA)
Infusion Nurses Society
Society for Healthcare
Epidemiology of America
(SHEA)

www.ivnnz.co.nz
www.bcshguidelines.com

www.nice.org.uk
www.rcn.org.uk
www.socca.org

www.cdc.gov
www.idsociety.org/Index.aspx
www.ins1.org
www.shea-online.org
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Appendix B
Table 2
Survey Responses
Adult inpatient
Pediatric inpatient

7
(70%)
3
(30%)

Adult outpatient
Pediatric outpatient

Transplant
Blood Cell
Bone Marrow
Cord
Progenitor Stem Cell
Staff Education

Transplants per Year
62%
<50
85%
51-100
54%
>100
85%
100% Patient Education
Insertion
Use of Prophylactic Antibiotics 0%
Use of Tunneled Line
Insertion Bundle
Use of Antimicrobial Devices
Yes
60%
Yes
Unknown
40%
Unknown
Under Ultrasound Guidance
Placement
Always
30%
By a Physician
Unknown
70%
By a Specialty Nurse
Preferred Site
Preferred Number of Lumens
Physician Choice
30%
Two
No Preference
30%
Three
Right Subclavian
20%
Left Subclavian
10%
Right Intra jugular
10%
Routine Care and Maintenance
Use Dressings
100% Managing Patency
Gauze (changed every 2 days 100%
Flushing with Normal Saline
when used)
Heparin Locking
Transparent (changed
90%
Locking with Normal Saline
weekly
40%
Alteplase
when used)
(Suspect/Known Occlusion)
None (after tunnel healing)
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3
(30%)
1
(10%)
30%
30%
40%
80%
80%
10%
50%
90%
10%
40%
60%

100%
90%
10%
100

Appendix B (Continued)
Dressings Changes
Performed By
Registered Nurse
Licensed Practical Nurse
Patient
Family/Lay Caregiver
Specialty Nurse
Physician
Nursing Time for Dressing
Change
15 minutes or less
15-30 minutes
Removal By
Physician
Specialty Nurse
Registered Nurse
Prompt Removal When no
Longer Necessary

100%
10%
30%
50%
20%
10%

Preventing Infection
Covering in Shower
2% Chlorhexidine Skin Prep
70% Alcohol Skin Prep
>.5% Chlorhexidine Skin Prep
Antimicrobial Locking
(known infection)

80%
60%
30%
10%
60%

60%
40%

90%
10%
10%
80%

Removal
Replacement Indicated
Known Infection
Known Occlusion
Malfunction
Unresolved Complication
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100%
90%
80%
20%

Chapter Three: The Economic Burden of Catheter-Related Bloodstream Infection
in Canadian Blood Stem Cell Transplant
Abstract
Catheter-related bloodstream infection (CRBSI) is associated with increased healthcare
spending and patient morbidity. The purpose of this study was to estimate the direct
inpatient charges for CRBSI in Canadian blood stem cell transplant recipients with a
tunneled Central Venous Catheter (CVC). A case-controlled comparison of records
indicating CRBSI and records not indicating CRBSI was used to quantify charges across
the following domains: length of stay, laboratory tests, diagnostic tests, medications
used, consults to a specialty physician, catheter replacement costs, and length of stay in
the Intensive Care Unit. Infections reduced the length of catheter use time by an average
of 13.51 days. Patients with CRBSI stayed on average an extra 19.81 days in the
hospital, resulting in extra charges of $40,986 for base 24-hour stay. Extra fees for
directly diagnosing and treating CRBSI averaged $4,683.90. Thus, the total estimated
burden of CRBSI in Canadian blood stem cell transplant for the 2013 fiscal year was
$45,670.79 per incident.
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Chapter Three: The Economic Burden of Catheter-Related Bloodstream Infection
in Canadian Blood Stem Cell Transplant
Microbial resistance confronts efforts to control infection in healthcare. Coupled
with patient acuity, infection further strains organizational budgets. Cancer patients
possess intrinsic risks for infection with compromised immune function being the most
serious (Bereket et al., 2012). A central venous catheter (CVC) is commonly used in
cancer care for delivering therapeutics and blood sampling (Scales, 2011). The devices
provide a direct portal to the bloodstream and because of this there is a potential for
contamination. Boersma and Schouten (2010) caution against acquiescence of infection
with healthcare technology. Infection control measures can be effective for ensuring
safety with the use of medical devices including a CVC.
Patrick et al. (2013) found central line infection is grossly under-reported
compared to the findings from the audits of medical records. This finding undermines
ethical accountability in healthcare provision. Scrutiny of hospital infection rates
challenges administrators to ensure control measures are positively influencing outcomes.
Certain hospital-acquired infections are avoidable with evidence-based prevention
strategies that target extrinsic risk factors (Bereket et al., 2012). Hand washing for
example, reduces transfer of microbes from one surface to another. Due diligence in
preventing infection alleviates morbidity and mortality risks that are especially
threatening to cancer patients. Currently, the costs of catheter-related bloodstream
infection (CRBSI) in blood stem cell transplant are unknown. The purpose of the study
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was to estimate inpatient direct medical care charges for CRBSI in Canadian
blood stem cell transplant recipients with a tunneled triple lumen subclavian CVC.
Review of the Literature
CRBSI
Catheter insertion, handling connections, or (rarely) infusions are all gateways for
transmission of pathogens (O’Grady et al., 2011). Bacterial affinity for surfaces in the
form of biofilm may also colonize onto catheter surfaces causing infections that are
problematic to eradicate (Yasuhiko et al., 2012). Determining that an infection is related
to a catheter involves assessment and ruling out all other potential sources. The
Infectious Diseases Society of America (IDSA) cites criteria for diagnosing CRBSI,
which practice consultants distinguish as different than a central-line associated
bloodstream infection (CLABSI) (O’Grady et al., 2011; Mermel et al., 2009). Lab
confirmation using comparative blood cultures with differences in growth time and
overall quantity of organisms more accurately reflect if organisms are sourced in (and
likely introduced from) a catheter (CRBSI) versus surface seeding or introduction from
other portals (CLABSI).
Cost
The majority of cost analyses report findings from intensive care settings. The
Centers for Disease Control and Prevention (CDC) reported in 2005 that the cost of a
single CLABSI exceeds $25,000 United States Dollars. Hsu et al. (2013) note cost
differences vary widely, depending on hospital reimbursement rates in multi-payer
healthcare models. In addition to the payment model Table 3 summarizes costs reports of
a single incident with varying estimates due to currency values, clinical population, and
timing of the research.
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Authors/
Year
Orsi, et al.
(2002)

Table 3
Case Control Cost Analyses of a Single Central Line Infection
Country
Cost
Population
Measures
Italy

€16,356

Liu et al.
(2002)
Rosenthal,
et al.
(2003)
Shannon et
al. (2006)

Taiwan

$NT66, 302

Argentina

$4, 888

United
States

$26, 839

Higuera et
al. (2007)

Mexico
City

$11,591

Tarricone,
et al.
(2010)

Italy

€9,154

Dal Forno
et al.
(2012)

Brazil

$89, 886

Raschka, et
al.
(2013)

Canada

$19, 776

ICU
(surgical)

Extra charges for extended
length of stay and infection
treatment
Renal Dialysis
Extra charges for extended
length of stay
ICU
Extra charges for extended
(medical/surgical length of stay, and
and coronary)
antibiotics
ICU
Extra charges for length of
(medical and
stay, antibiotics,
coronary)
laboratory/diagnostic tests,
related procedures, and nonnursing healthcare labor
ICU
Extra charges for extended
length of stay and
antibiotics
ICU
Extra charges for extended
(4 different
length of stay, medications,
specialty areas)
supplies, lab tests, and care
by an infection specialist
ICU
Difference in mean total
cost of care including extra
length of stay and resources
until hospital discharge
Inpatient
Charges for extended length
(non-ICU)
of stay

$= Dollars; €= Euros; $NT=New Taiwanese Dollars

A basic tenet within modern microeconomic theory regards value synonymously
with the price of a commodity (Nicholson & Snyder, 2012). Cost factors in healthcare
can be direct or indirect. Arguably, value in healthcare transcends consumerism given
the inability to appraise both human lives and diverse costs associated with affliction.
Indirect costs such as suffering, loss of life, or missed opportunities are difficult to
quantify in terms of infection outcomes. Conceptualization of healthcare as a commodity
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ensues as access and bottom lines inevitably converge. Direct medical costs are defined
by Santerre and Neun (2010) as charges to the payer for tests, exams, treatment, and
provision of care etc. Identifying direct medical charges for specific adverse outcomes
can be useful in cost-benefit analysis and designing research.
Canadian Cost Factors
The Canadian healthcare insurance plan is a universal model designated by public
authority and delivered on a non-profit basis (Health Canada, 2013). The Canada Health
Act (1985) stipulates that hospital services include: accommodation and meals, services
by all personnel employed within the institution, laboratory/radiology/diagnostic
procedures and interpretation, drugs, supplies, and preparations, medical equipment and
surgical supplies, full operative procedures and care for all services deemed medically
necessary for maintaining health. Fees for treating adverse events are absorbed within
departmental operating budgets. Observational research of past events puts cost
containment into perspective by conveying the capital benefits of preventing adverse
events. CRBSI (the independent variable of the study) incurs extra charges (dependent
variable). Beyond prolonged hospital stays, care for CRBSI may include additional
medications, laboratory tests, diagnostic tests, specialty consultation, and supplies
(O’Grady et al., 2011; Tarricone, Torbica, Franzetti, & Rosenthal 2010). Quantifying
how individual resources are being used to treat CRBSI allows for cost estimations
within universal funding models that may influence administrative decisions.
For the purposes of this study CRBSI is operationally defined as a diagnosed
bloodstream infection when no other source is apparent and confirmed by comparative or
paired blood culture results with a time to positivity of 120 minutes or greater and/or
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threefold difference in microbial load (Mermel et al., 2009). The dependent variable,
charge, is operationally defined as the Canadian dollar value for allocated resources
(including inpatient hospital bed and all associated inpatient care, medications, laboratory
and diagnostic tests, supplies for line replacement, stay in the intensive care unit, and
services of a specialty physician) required for treating a confirmed CRBSI.
Research Questions
The cost of a CRBSI in Canadian blood stem cell transplant recipients with a
tunneled CVC has not been reported in the literature. This study addressed the following
questions. Among Canadian blood stem cell transplant recipients with a long term
tunneled triple lumen subclavian CVC:
1. Is CRBSI associated with an extended hospital stay?
2. What are the average extra charges for diagnosing and treating CRBSI?
3. What is the average total charge for a single CRBSI?
Methods
Design
Expedited institutional review board (IRB) approval for the study with a waiver of
consent was granted from both academic and health care institutions. A retrospective
case-control comparison analyzed healthcare spending between two groups. The case
group included records with documented incidents of CRBSI. The comparison group
included matched control records with no documented incidents of CRBSI.
Sample/Setting
The study sample consisted of medical records of blood stem cell transplant
recipients with a tunneled triple lumen subclavian CVC, treated in a single adult
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Canadian blood stem cell transplant program between 2008 and 2013. Inclusion criteria
for both groups stipulated the use of a tunneled CVC, completion of transplant, and
documented CVC removal, as well as a confirmed CRBSI for the case group. One
additional criterion for records in the control group stipulated no documented incidence
of CRBSI. Several exclusion criteria were applied to both groups in sample selection to
eliminate potential cost influences. Records indicating simultaneous use of vascular or
invasive catheters, more than one isolated CRBSI, tunnel infection, and multiple
transplants, were excluded. Records indicating other line-associated complications
(occlusion, thrombosis in the superior vena cava, and accidental displacement) were also
excluded alongside records with no comparable control. Selection generated 133 pairs
for a final sample size of 266.
Instruments
Data was coded into an electronic dataset designed specifically for the study as no
existing instrument was identified. Clinical records and financial documents sourced the
data yield. Base charges to the public payer for blood stem cell transplants, medical tests,
hospital stays, intensive care stays, procedures, and specialty consult fees for the 2013
fiscal year were used to measure direct charges. Other monetary data for the 2013 fiscal
year that were billed to the public payer were obtained through inpatient pharmacy
inventory list that reports charges per dose of medications used and manufacturer contract
pricing (confirmed by the manufacturer) for central venous catheters.
Procedure
All records were de-identified for any personal information in accordance with
ethics regulations. Demographics, length of stay, and length of time each catheter was in
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place were transcribed from electronic and hard copy records and recorded for both
groups. All positive blood culture results were reviewed to confirm CRBSI according to
pre-set study criteria and assigned to the case group. For case records, physician notes
and medical orders were further catalogued for actual usage of resources specifically
indicated for diagnosing and treating CRBSI. Charges were tallied by frequency of use
according to set Canadian dollar values billed to the public payer for the 2013 fiscal year
in the following domains: (1) length of stays, (2) laboratory tests, (3) diagnostic tests, (4)
medications, (5) fees for insured procedures or consultations by a specialist physician, (6)
replacement catheters, and (7) length of stays in the intensive care unit due to CRBSI.
Additional supplies for delivering treatment (i.e. intravenous sets, infusion bags, cold
packs etc.) were included as part of the daily hospital fees that are covered by the
inpatient nursing unit budget.
Similar to other observational studies, case records were paired with controls to
enhance comparability of groups. Control criteria were applied for matching each case
record to a counterpart in age (+/- five years), gender, and type of transplant (autologous
or allogeneic), diagnosis, type of stem cells, and treatment protocol. Controls were
purposively selected for exact matches on four or more criteria. The Statistical Package
for the Social Sciences (SPSS) Version 21 was used for data analysis (International
Business Machines Corporation, 2010). The parameters for statistical significance were
pre-set at α of .05 and β of .80. Non-parametric tests were used to analyze data in
violation of assumptions for statistical tests.
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Results
The final sample of 133 case-control pairs (n = 266) were subjected to 31,110
catheter days (M 117, SD = 87.63). Nineteen different treatment protocols were used for
transplant conditioning. Sample characteristics are summarized in Table 4. Independent
t tests show no significant differences in age or body mass index between groups.
Although there were more males than females in the sample, the gender dispersion
between groups was similar given non-significant Chi square results. Chi square tests
also did not indicate group differences in diagnosis, type of transplanted cells, or
treatment between case and control groups.

Variable

Age

Table 4
Demographic Comparisons Between Case and Control Groups
Descriptive
Independent t
Chi Square
(M, SD, %)
t
df
p
χ²
df
p
M 50.56 ± 11.92

BMI

-.180

264

.858

-.717

264

.474

M 25.15 ± 5.54

Gender
Male
Female
Diagnosis
*Other
Leukemia
Lymphoma
Cell
Allogeneic
Autologous
Treatment

159 (59.8%)
107 (40.2%)

.141

1

.803

70 (26.3%)
110 (41.4%)
186 (32.3%)

0

2

1

150 (56.4%)
116 (43.6%)

0

1

1

20.74

18

.255

*Other malignancy or blood disorder requiring blood or marrow cell transplant

Table 5 lists the numerous different organisms that were detected in the case
group. Five cultures grew two different organisms, two cultures grew three different
organisms, and one culture grew four different organisms. Seventy of the organisms
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were classified as gram stain positive, 74 gram stain negative, and one gram stain was
unknown. The most frequently occurring infections were Staphylococcus genus (n=42),
Escherichia Coli (n=25), Klebsiella (n=17), and Streptococcus species (n=14).
Table 5
Cultured Organisms in Cases of CRBSI
Abiotrophia Defectiva
Acinetobacter
Acinetobacter Baumanni
Acinetobacter Hydrophillia
Bacillus Cereus
Brevibacterium
Candida Kreusei
Candida Paropsilosi
Citrobacter Freundii (complex)
Citrobacter Kosari
Clostridium Septicum
Coryneform
Diplococci
Escherichia Coli
Escherichia Cloacae
Enterobacter Aerugenosis
Enterococcus
Enterococcus Faecalis
Enterococcus (VRE)
Fusobacterium
Granulicatella
Haemophilus Influenza
Haemophilus Parainfluenza
Klebsiella Pneumoniae
Klebsiella Oxytoca
Leptotrichia Buccalis
Moraxella Catarrhalis
Pantoea Species
Pseudomonas
Pseudomonas Aerugenosa
Pseudomonas Oryzihabitans
Rhizobium Radiobacter
Roseomonas
Serratia Marcescens
Staphylococcus
Staphylococcus Aureus
Staphylococcus Capnocytophagia
Staphylococcus (CNS)
Staphylococcus Ludguenesis
Staphylococcus (MRSA)
Staphylococcus (MSSA)
Stenotrophomonas
Streptococcus
Streptococcus Group B
Streptococcus Group G
Streptococcus Mitis
Streptococcus Viridians

One
1
2
1
1
1
1
1
1
1
1

Two

Three

Four

1
1
1
22
5
1

2
1

1

1
2
1
1
1
1
1
16
1
1
1
1
2
2
1
2
1
1
2
7
1
28
2
1

1

1

2

1
2
2
4
1
6
1

1
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Total
1
2
1
1
1
1
1
1
1
1
1
1
1
25
6
1
1
2
1
1
1
1
1
16
1
1
1
1
3
2
1
3
1
1
2
9
1
28
2
1
1
2
2
5
1
6
1

Control group records indicated 1,798 more catheter days than case group records
with a mean difference of 13.51 days. Case records also indicated line replacement with
a tunneled catheter on 22 occasions, a percutaneous intravenous central catheter (PICC)
on 33 occasions, and an intra-jugular (IJ) catheter on seven occasions for a total
requirement of 62 new lines (46.62%). Five records indicated ICU admission for
infection. Eight cases and nine controls indicated demise with a CVC in situ.
The majority of the sample (n=253) exceeded the base allotment of hospital days
for transplant with two records indicating discharge as estimated, eight discharges one
day early, and three discharges two days early. Table 6 shows that inpatient length of
stay ranged from 14-313 days. Mann Whitney U tests show there were significant
differences in length of hospital stay (U = 6456, z = 3.664, p = <.001 r = .22) and
subsequent costs of hospital stay (U = 6319, z = 4.027, p = <.001, r = .23) between
groups, with longer stay and higher expenses associated with the case group. The case
group stayed on average 19.81 days longer in the hospital than the control group.
Table 6
Catheter Days and Length of Stay in Case and Control Groups
Median
Range
SD
Mean
Difference
Catheter Days
Case
83
6-413
93.16
110.2
Control
93
18-424
81.52
123.71
13.51 days
Total
92.5
6-424
87.63
116.95
Length of Stay
Case
53
15-313
54.48
71.89
Control
39
14-269
52.08
52.08
19.81 days
Total
45.5
14-313
48.6
61.99
Results of a Mann Whitney U test also revealed significant differences in total
charges between groups (U = 5759, z = 4.96, p<.001, r = .30). The mean difference in
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hospital stays of 19.81 days in the case group carried a price tag of $40, 986.89. Extra
charges for treating infection ranged from $70.60 to1$198, 993.63 with a mean extra
charges totaling $4, 683.90 (Median $708.5, SD $23, 803.51). The total estimated
charges for a single infection considering fees for the mean extra length of stays and extra
charges for actual resource usage were $45, 670.79.
Discussion
Results from the case control study of CRBSI in a single Canadian blood stem
cell transplant centre reveal significant cost implications to both the program and the
patient. Quality of life costs of CRBSI unmeasured by the current study deserve
consideration. While the centre must absorb charges of $45,670.79 on average, the
patient costs of discomfort with line replacement, time spent away from loved ones while
in the hospital, and the symptom experiences of infection, to name a few, may be valued
by individuals beyond monetary worth.
CRBSI in the case group is associated with shortened catheter life which
coincides with practice guidelines that recommend line removal depending on the overall
clinical picture and with certain organisms (Mermel, 2009). Studies comparing costs of
salvaging lines versus replacement are needed to further inform practitioners in costeffective decision making. Dibb et al. (2012) concur that removing a line on account of
complications is not always necessary or possible as it may be needed for emergent
rescue or may cause needless discomfort when simple treatments are possible. The
tunneled catheters used in the sample population are designed for long term use (>90
days), and the mean length of use surpassed this time frame in both study groups (Joint
Commission, 2012). Maintaining the integrity of the line without infection is possible as
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several cases and controls retained a CVC for a year or longer. Care efforts should target
prevention of infection over reactive management.
Although results indicate small effect size for the difference in length of stay
between groups it was the most expensive charge. Intrinsic risk, namely compromised
immunity, may explain part of the additional hospitalization required in blood stem cell
transplant. However, in this study clear differences between groups make the case for
inference that infection is also associated with prolonged stay in this population which
coincides with past study findings (Dal Forno et al., 2012; Raschka, Dempster, & Bryce,
2013).
Effect size increased when considering total charges for diagnosing and treating
infection. The need for intensive care support in five cases inflated the range of charges
followed by medication use, and replacing the CVC. The wide variation in total charges
also reflects the complexity of care required in the blood stem cell transplant population,
the nature of different organisms, and difficulty in predicting individual care needs.
Nearly all (95%) of the sample exceeded allotted hospital days included in the base price
of transplant which suggests program funding is grossly underestimated.
The abundance of different organisms responsible for CRBSI in the sample may
explain part of the wide variance in charges for treating CRBSI. Staphylococcus genus is
the most widespread nosocomial pathogen within the study sample and globally (Bereket,
2012). Multi drug resistant gram negative organisms in the sample, such as
Acinetobacter Baumanni, Stenotrophomonas Maltophilia and Pseudomonas, are known
to have changing dynamics in cell function and the ability to resist current treatments
(Bereket, 2012). This study did not show increased treatment costs with more resistant
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gram stain negative types of organisms; rather, four of the five cases were admitted to the
ICU with gram positive Staphylococcus genus organisms (none of which were identical)
and one case of a fungal infection. Higher costs may be due to the onset of infection at a
more vulnerable time in the treatment process. The nadir of chemotherapy conditioning,
graft versus host disease, prolonged neutropenia, or relapse/graft failure that were not
controlled for within this study beyond matching cases and controls; however, length of
stays and extra charges were observed to be higher with related donor transplants,
followed by unrelated donor transplants and lastly, self-donations. Cost analyses that
distinguish infection outcomes and associated fees between allogeneic and autologous
recipients are worth future research attention.
In addition to limitations noted in the discussion above, retrospective observations
limit the ability to isolate causal relationships. Stringent matching criteria were
implemented to offset validity threats by controlling group comparability. A second
factor not considered in the study was that records were not audited beyond line
replacement with non-tunneled catheters. Similar analyses with other catheter types have
the potential to further inform practitioners on the best type of intravenous device to use
post-transplant should tunneled CVC complications occur. Indirect costs to patients and
the system, and associated cost for symptom management on an as needed basis were
also not measured in this study; however, it is more likely that these considerations would
inflate rather than reduce the overall estimate.
Summary
Curtailing hospital infection is not a new issue in healthcare. However, charges
continue to inflate, outdating past cost-analyses. This study found that in 2013, CRBSI in
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a Canadian blood stem cell transplant centre increased resource allocation, shortened
central venous catheter life by an average of 13.51 days, extended hospital stays an
average of 19.81 days, and incurred average charges of $45, 670.79 per incident. It is
reasonable to expect similar results across Canadian blood stem cell transplant programs
and with other bloodstream infections with the exception of fees incurred for CVC
replacement. Costs may be lower in less acute areas and among populations that are not
faced with immune system compromise.
The relatively small stem cell transplant population is a large contributor to
healthcare spending. Reassessment of base funding in support of the program is needed
alongside research targeting infection reduction. Nursing studies examining practice
strategies aimed at reducing thrombo-infective complications with CVC care may be
invaluable assets to cost containment. Findings from this study may be useful for
estimating cost avoidance in research of clinical interventions that lead to a reduction in
CRBSI and other device-associated bloodstream infections.
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Chapter Four: Analysis of Costs and Benefits of Tunneled Central Venous Catheter
Dressings in Canadian Stem Cell Transplant Recipients
Abstract
Catheter-related bloodstream infection (CRBSI), an avoidable risk in cancer nursing,
contributes to patient morbidity, and increases health care spending. The objective of the
study was to evaluate the impact of three different nursing care strategies for tunneled
central venous catheter (CVC) exit sites on infection outcomes and compare costs of each
strategy. The study hypothesis proposed that CRBSI and charges for nursing care differ
in Canadian blood and marrow cell transplant recipients with a tunneled CVC that use a
transparent dressing, no dressing, or a gauze dressing. A sample of 432 records at a
single centre compared CRBSI between dressing groups. A micro-costing approach was
used to estimate dressing supply charges for an evaluation of the costs and benefits of
each exit care strategy. Results of the study indicated no significant differences in
CRBSI, number of organisms, gram stain of organisms, development of infections before
or after tunnel healing, or onset of infection between the three dressing groups. In terms
of supplies alone, transparent dressings were most economical, followed by no dressing
and lastly, gauze. The no dressing strategy was the most cost-effective alternative to
using a transparent dressing.
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Chapter Four: Analysis of Costs and Benefits of Tunneled Central Venous Catheter
Dressings in Canadian Stem Cell Transplant Recipients
Infection control, essential in minimizing healthcare costs, continues to challenge
healthcare providers. Risk of infection is particularly concerning in blood stem cell
transplant recipients given their weakened immune function and dependence on
prolonged vascular access (Tomblyn et al., 2009). Nearly all blood stem cell transplant
patients receive a tunneled central venous catheter (CVC) to facilitate life-saving
treatment as it poses the lowest infection risk of all long term catheter choices (Faruqi et
al. 2012; Scales, 2010a; Toscano et al., 2009). Catheter-related bloodstream infection
(CRBSI) is typically associated with morbidity and expense rather than fatality (O’Grady
et al., 2011). Blood stem cell transplant nurses are influential in preventing CRBSI as
they manage and educate others on CVC care. Cost-benefit analysis considers how much
and to what degree expected costs outweigh the total expected benefits (Santerre & Neun,
2010). Different care strategies do not posit equal expenditure. The effects and charges
to the public payer for various exit site care strategies performed by registered nurses on
infection outcomes are unknown in Canadian blood stem cell transplant.
A tunneled CVC features a cuff placed under the skin with the proximal end
resting in the superior vena cava and a salient distal end (Scales, 2011). Immediate
placement of a sterile dressing after CVC insertion secures the device until the cuff
embeds into the surrounding tissue (tunnel healing), and protects the puncture sites
(Macklin, 2010; Poole, 2010; Scales, 2011). Practice consultants such as the Infusion
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Nurses Society (INS), claim a dressing on a healed CVC tunnel is unnecessary
while others including the American Centers for Disease Control and Prevention (CDC)
posit that they can make no recommendation on the issue (INS, 2011; Joint Commission,
2012; O’Grady et al., 2011; Scales, 2010b; Toscano et al., 2009).
Dressing options should meet patient needs and provide equal protection against
infection risks. Evidence of the clinical effectiveness of CVC exit site care in regards to
CRBSI is limited. The feasibility of certain nursing strategies must also be evaluated
within the economic capacity of the financing system (Tarricone, Torbica, Franzetti, &
Rosenthal, 2010). Canadian CRBSI cost estimates (for all central venous catheter types)
exceed $19,000 per incident (Raschka, Dempster, & Bryce, 2013). A recent analysis by
the author suggested CRBSI costs for Canadian blood stem cell transplant patients
exceeded $45,000 per incident in 2013 (Keeler, in review). Carefully weighing cost-toclinical benefit supports accountability in publicly funded healthcare. Expected fees
associated with adverse events and nursing care may strongly influence practice
decisions. The purpose of this study was to evaluate the impact on CRBSI and costs and
benefits of nursing exit site care for Canadian blood stem cell transplant recipients with a
long-term tunneled triple lumen subclavian CVC.
Review of the Literature
CRBSI
CRBSI can develop from systemic microbes adhering to the catheter surface or
the introduction of organisms on insertion, manipulation, or infusion (O’Grady et al.,
2011). A primary bloodstream infection is deemed a CRBSI when an alternate source
cannot be determined in a patient with a CVC in place for 48 hours or longer (Chopra,
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Krein, Olmsted, Safdar, & Saint, 2013). The most accurate diagnostic measure of CRBSI
found by meta-analysis is paired blood cultures (Rodriguez et al., 2012). The measure
compares a CVC blood sample to a peripheral sample from the same individual. Samples
are grown in a media to detect and identify organisms. Positive CVC results with
negative peripheral results are strongly indicative of a catheter source of infection. A
difference in growth time-to-positivity between samples or three fold or greater microbial
load in one sample also indicate the location of an infection (Mermel et al., 2009). Paired
blood cultures distinguish CRBSI from disease and treatment-related symptoms that a
CVC was designed to manage (Macklin, 2010; O’Grady et al, 2011; Tomblyn et al,
2009).
Dressing
Popular CVC dressings are made of cotton fiber (gauze) or polyurethane
(transparent). A gauze dressing covers the exit site with or without securement. The
adhesive on one side of a transparent dressing attaches directly to the catheter and
surrounding skin. Dressings act as a barrier between the puncture site and the external
environment. Microbes naturally collect in the first five layers of the stratus corneum,
hair follicles, and sebaceous glands, and can re-colonize within 48 hours of disinfecting
necessitating dressing changes (Macklin, 2010). Guidelines recommend changing a
gauze dressing every two days and transparent dressing no more than once every seven
days unless either is wet or soiled (O’Grady et al, 2011).
The most recent Cochrane review reports a wide range of increased CRBSI with
the use of transparent dressings, even while considering research bias (Gillies,
O’Riordan, Sheriff, & Rickard, 2011). Issues such as comparing different central line
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types across different populations, lack of reporting effect size, lack of reporting missing
data, and including overlapping variables are mentioned as result-limiting factors. None
of the research in the meta-analysis compared dressing types to undressed sites.
Preliminary studies report that dressings are predictors of CRBSI in renal and intensive
care populations compared to a no dressing group (Seiler & Pember, 2012; Toshiyuki et
al. 2012).
No Dressing
The debate for maintaining a dressing on a healed CVC tunnel began with a pilot
study reporting no difference in line infections in a small sample of cancer patients
without exit site dressings (Petrasino, Becker, & Christiansen, 1988). One random
controlled trial by Olsin et al. (2004) revisited the issue. However, the small sample and
early closure requires additional evidence to support practice recommendations based on
study findings. This current state of the science contributes to questionable evidence
guiding nursing care as approximately 40% of Canadian blood stem cell transplant
centres reported in 2013 that their policy is to remove the dressing from a healed tunneled
CVC site (Keeler, 2014).
Additional Care Strategies
Alternatives for preventing CRBSI can be found in the literature. Applying honey
to the exit site has not been reported to significantly reduce CRBSI (Kwakman et al.,
2012). More popular is trialing medical products and antiseptic solutions with varying
reports of significance (O’Grady et al., 2011; Popovich, Hova, Hayes, Weinstein, &
Hayden, 2010). Antibiotic ointment under the dressing in the blood stem cell transplant
population is counterproductive as it is known to increase drug resistance and
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colonization of fungi in immune compromised hosts (O’Grady et al., 2011; Tomblyn et
al., 2009). Allergies, skin toxicities, and age younger than two months may render use of
adhesive and antiseptic patch dressings inapplicable (Battistella, Bhola & Lok, 2011;
Daniels & Frei, 2012; Tomblyn et al., 2009). Antimicrobial coated lines and impregnated
cuffs are now available (Bard, 2012a; Bard, 2012b). Practice consultants only
recommend use of these products if all other prevention efforts fail to decrease CRBSI
incidence (O’Grady et al., 2011).
Theory
Duval (2010) summarizes the evolution of Lister’s 19th century theory of asepsis
that continues to guide clinical practice and research today. The theory outlines human
and animal coexistence with microorganisms that may be innocuous or cause illness.
Pathological transfer of microorganisms can be prevented by natural immunity,
inoculation, interrupting the cycle of transmission, or decreasing microbial load.
Application of the theory has evolved into common reference to the principles of asepsis
that are modeled in Figure 1. Conformity to aseptic principles incorporates preventing
exposure and/or any activities or techniques that aim to decrease or eliminate microbial
presence. Examples include avoiding contact, inoculation, maintaining a dry
environment, or using products and strategies for sanitization, disinfection, or
sterilization (Lister, as cited by Beck, 1895; Macklin, 2010; Medeiros, dos Santos,
Soares, Costa, & Lira, 2012; Pallo, 2012; Scales, 2011).
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Avoided
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Resolved

Figure 1. Model of Lister’s Asepsis Theory
Judgment is required for applying aseptic principles in clinical care. For example,
the aim of inoculation is exposure to certain organisms to stimulate an immune response
should repeat exposure occur. Infection prevention strategies are multifaceted depending
on clinical context and body of epidemiological knowledge. Avoiding infection requires
conscious multidisciplinary efforts and actions at all stages of care and treatment in blood
stem cell transplant.
Variable Selection
Study variables were selected after consideration of all other strategies
incorporating aseptic principles with CVC access already in place at the study centre.
The bundling strategy is used for catheter insertion. This strategy includes proper hand
hygiene, using maximum barrier precautions (sterile gown, drape, gloves, equipment, and
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wearing a mask), using a >0.5% chlorhexidine skin prep solution, choosing the
appropriate site if known and a daily review of the necessity of the catheter with prompt
removal when no longer essential (Faruqi et al., 2012; Moreau, 2009). In addition to the
bundle strategy for insertion, all catheters are placed by a radiologist under ultrasound
guidance.
Policy and nursing standard operating procedures at the study site mandate nearly
all CDC recommendations for CVC practice and incorporate several principles of asepsis.
Initial and yearly education for CVC competency is required in accordance with program
accreditation standards. The support of both clinical nurse educators and experienced
clinicians is available for staff skill certification and troubleshooting catheter-related
complications. Prior to delegating the task, registered nurses assess patients’ and lay
caregivers’ competency with exit site care by return demonstration. CVC access,
infusions, and manipulations are performed via a needleless luer piggyback system with
replacement of all infusion sets every 24 hours if the system is interrupted and every 72
hours if the system is uninterrupted. Sterile technique is mandated for dressing and cap
changes with use of a sterile mask, gloves, and supplies, and 2% chlorhexidine skin
antiseptic. Hand hygiene is routinely audited by the infection prevention and control
department, and standard operating procedure mandates an alcohol scrub-the-hub for 15
seconds strategy for sterilizing connections prior to accessing infusion ports.
A policy change in 2011 incorporated removing the dressing from healed
tunneled exit site and use of protective coverings over puncture sites and connections
during showering. Prior to the current policy, transparent dressings were used when
adhesive was tolerated; gauze dressings were used for individuals with skin sensitivities.
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After the policy change all patients were instructed to remove the dressing after tunnel
healing.
In spite of adherence to CDC guidelines and asepsis, CRBSI still occurs.
According to the Institute for Healthcare Improvement (IHI), a CRBSI is criterion based
infection diagnosed when no other source is apparent (2013). Confirmation that an
infection is related to a CVC is obtained through comparative blood cultures. The
Canadian Nosocomial Infection Surveillance Program (CNISP) criteria (2005) were used
to operationally define CRBSI as the dependent variable for the study. The independent
variable was the type of exit site care provided for a tunneled CVC at three levels:
transparent dressing, no dressing after tunnel healing, or gauze dressing. The literature
revealed a gap in the evidence regarding dressing maintenance after tunnel healing which
generated the study hypothesis that there are differences in CRBSI and charges for exit
site care strategies for Canadian blood stem cell transplant recipients with a long term
tunneled triple lumen subclavian CVC that use a transparent dressing, no dressing, or
gauze dressing.
Methods
Design
Following study approval by institutional and health board ethics committees,
archived data from a single Canadian transplant centre was accessed. The posttest-only
control group design was used to compare the dependent variable (CRBSI) after a
specific treatment condition (type of dressing) among groups. A micro-costing approach
was used to estimate the charges to the public payer for using a transparent dressing, no
dressing, or gauze dressing, according to supplies and frequency of care.
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Sample/Setting
The clinical records of adult blood and marrow cell transplant recipients from a
single Canadian centre treated between 2008 and 2013 were reviewed. Documents
noting completion of blood and/or marrow cell transplant and use of a long term tunneled
cuffed triple lumen subclavian CVC were included in the sample. Records with absent
documentation for line removal were excluded alongside records indicating catheters still
in place. Additional exclusion criteria included known source of infection, multiple
catheters at once, and non-adherence to standard policy and procedure for exit site care.
All eligible records indicating dressing removal after tunnel healing were included in the
sample. A purposive sample of records indicating the use of a gauze dressing or use of a
transparent dressing were randomly selected until all three groups were equal in number.
The transparent group (the largest group overall) was further stratified until overall
gender dispersion was similar (N=432).
Instruments
Blood culture results were interpreted and confirmed using federal surveillance
standards for reporting hospital acquired infections and practice recommendations from
the Infectious Diseases Society of America (CNISP, 2005; Mermel et al., 2009).
Electronic flow sheets and multidisciplinary progress notes were consulted to confirm
individual dressing strategies. Nursing CVC policy and procedure and inventory price
lists for supplies were used as measures for estimating weekly charges for each dressing
strategy.
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Procedure
Study data was de-identified and converted to an electronic data set. Analysis
was performed using the Statistical Package for the Social Sciences (SPSS) Version 21
(International Business Machines Corporation, 2012). An inventory list indicating prices
for supplies that were billed to the public payer by the inpatient blood stem cell transplant
nursing unit was accessed. Charges for all supplies listed in the nursing policy and
procedure document and unit standard operating procedures were tallied according to
dressing strategy: for example, gloves, chlorhexidine swab sticks, dressing type, shower
covers etc. Weekly costs were determined according to policy with transparent dressings
changed after seven days, daily care after showering for the no dressing group, and gauze
dressings changed after 48 hours. Individual dressing costs were estimated by
multiplying the weekly cost of the dressing strategy used by the number of weeks the
catheter was in place. Individual costs were adjusted for use of securement devices (once
a week) and initial care post insertion (mean cost for the no dressing groups until tunnel
healing set at day 14). Parameters for statistical significance were set at α at .05 and β at
.80. The analysis of variance test was used to compare differences in CRBSI between
groups. Kruskall-Wallis tests were used to analyze data in violation of assumptions for
parametric statistics, and the Chi square test was used to analyze categorical data.
Results
The final sample represented 46,496 catheter days (M 107.63, SD 74.86) for 432
recipients of allogeneic (46.53%), autologous (53.01%), and syngeneic (.46%) blood
and/or marrow cell transplant. Overall, Table 7 shows there were similar numbers of
males and females in the entire sample; however, dressing dispersion by gender was not

53

equal. Analysis of variance tests were non-significant when comparing groups according
to age F (2) = .489, p = .614, and body mass index F (2) = 2.849, p = .059. Chi square
results also showed no significant differences in general diagnosis between groups, χ² (4)
= 5.884, p = .208.

Male
Female
Age
BMI
Leukemia
Lymphoma
Other
Allogeneic
Autologous
Syngeneic
Catheter Days
M, SD
Infections
Incidence
*Prevalence

Table 7
Study Sample Characteristics and Catheter History
Transparent
No
Gauze Dressing
Dressing
Dressing
42
93
78
102
51
66
49.65±13.34
51.15±12.95
50.19±12.79
24.51±5.11
25.54±4.8
25.92±5.58
53 (36.8%)
40 (27.78%)
53 (36.8%)
46 (31.94%)
48 (33.33%)
52 (36.11%)
45 (31.25%)
56 (38.89%)
39 (27.08%)
72 (50%)
55 (38.2%)
74 (51.4%)
72 (50%)
88 (61.1%)
69 (47.9%)
0
1 (.7%)
1 (.7%)
16966
14116
15414
117.82±70.54
98.03±62.79
107.04±88.17
52
43
52
12.04%
9.95%
12.04%
3.06
3.04
3.37

Total
(N=432)
213
219
50.33±13.01
25.32±5.19
146 (32.4%)
146 (33.8%)
140 (33.8%)
201 (46.5%)
229 (53%)
2 (.5%)
46496
107.63±74.86
147
34%
3.16

Other= disease or malignancy treated with blood stem cell transplant
*Prevalence = number of infections per 1000 catheter days

All records indicated treatment with a conditioning chemotherapy protocol
followed by a blood stem cell transplant. Of the 432 patients, 129 individuals developed
147 separate CRBSIs (113 people with one infection, 14 people with two infections, and
two people with three infections). Multiple infections that met the criteria for being a
new infection were included in the analysis for a total incidence of 34% and prevalence
rate of 3.16 infections per 1000 catheter days. CVC replacement due to infection was
required in 70 cases (16.2%) and one record indicated demise was suspected from a
CRBSI.
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The lowest incidence rate for the no dressing group and highest prevalence rate
for the gauze dressing group indicated on Table 7 reveal there are slight differences in
infection outcomes according to dressing group. Comparative statistical tests in Table 8,
however, show that the differences between infection groups are non-significant.
Table 8
Infection Among Dressing Groups
Analysis of Variance
Kruskall-Wallis
F
df
p
ω
H
p
CRBSI
Number of
Organisms
Gram +
Organisms
Gram Organisms
Onset of
First
Infection
Onset of
Second
Infection
Onset of
Third
Infection
Stage of
Tunnel
Healing

.375
.700

(2,429)
(2,429)

.555
.497

.05
.06

1.104

(2,429)

.333

.07

.396

(2,429)

.673

.04

1.779

(2,429)

.17

.09

.285

(2,429)

.752

.04

2

Chi Square
χ²
p

1

6.558

.34

Analysis of variance results indicate there were no significant differences in the number
of infections, number of organisms, gram stain of organisms, or onset of infection among
groups. According to Field (2009) ω calculations more accurately estimates effect size
beyond the sample population because average variance is considered rather than using
numerator sum of squares of the model over denominator total sum of squares. The ω
values in Table 8 indicate that the average variance explained by the analysis of variance
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tests are minute, coinciding with non-significant findings of difference between groups.
There were also no significant differences in the number of infections before tunnel
healing (day 14), or after tunnel healing (day 15 and beyond) among groups as indicated
by the non-significant results of the χ² test.
Although overall effects of type of dressing on CRBSI are small, between group
comparisons in Table 9 reveal odds ratios (OR) and relative risks (RR) were higher in the
gauze and transparent groups than the no dressing group, with gauze and transparent
dressings resulting in equal risk. OR was determined by dividing the odds of developing
an infection in one group by the odds of developing infection in a different group.
Similarly, RR was determined by dividing the percentage of infection in one group by the
percentage of infection in a different group. The odds of developing an infection in the
gauze group were .58 times higher than the no dressing group. The odds of developing
and infection in the transparent group were also higher than the no dressing group by .25.
Relative risks for each group comparison show narrower differences between each
dressing group with a .21% higher risk when a gauze dressing versus no dressing is used,
and a .17 % higher risk of infection when a transparent dressing is used instead of no
dressing.
The abnormally distributed cost variables were analyzed with non-parametric
equivalent tests, namely the Chi square test for multiple group comparisons, and the
Mann Whitney U test was used in substitute of a parametric t test. There were significant
differences in costs of each care strategy, χ ² = 2.75.68 (df2), p <.001. Mann Whitney U
tests show gauze dressings (M $2059.7, SD 1660.81) cost more than no dressing (M
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$712.31, SD 501.312), and no dressing costs more than using a transparent dressing (M
$445.8, SD 682.32).
Table 9
CRBSI Risk and Cost Differences Between Dressing Strategies
CRBSI
Cost
Odds
Relative
Mann Whitney
Ratio
Risk
OR
RR
U
z
p
GD vs. ND
1.33
1.21
3784
9.32
<.001
GD vs. TD
1
1
1787
12.14
<.001
ND vs.TD
.75
.83
5381
7.06
<.001

r
.55
.72
.42

GD=gauze dressing, ND=no dressing, TD=transparent dressing

Discussion
Results from this study comparing the incidence of CRBSI among blood stem cell
transplant recipients whose tunneled catheter sites were managed with either gauze,
transparent, or no dressing suggest that the type of CVC exit site dressing is not
associated with infection in this population. However, supply charges for the different
dressing strategies were significantly different, with gauze dressings incurring the highest
costs to maintain ($ 59.10/week), followed by no dressings ($55.89/week), and lastly,
transparent dressings ($23.71/week). The overall costs and benefits of each strategy
require clinical judgment and consideration of negative outcomes, charges, and nonmonetary costs.
Study results indicate bloodstream contamination at the tunnel site is unlikely
when the site is kept dry beneath dressings or by dressing removal. Initial dressings
prevent exposure to host bodily fluids and catheter slippage until the tunnel site has
healed. O’Grady et al. (2011) suggest moisture catalyzes microbial tunnel migration and
increases surface colonization thereby advising to protect access sites from unsterile
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precipitation. Recommendations are based on case-reports of water borne infections
likely introduced via unprotected connections. Covering all sites and connections during
showering may be more influential on CRBSI reduction than the type of dressing.
It is further advised to use careful judgment with dressing maintenance for a
prolonged period of time (O’Grady et al., 2011). Clinical judgment is also needed for
dressing removal. Daily skin antisepsis, shower covers and using securement devices are
recommended strategies that incur charges. Medical products designed for these
purposes may not be feasible in low income countries or may be intentionally overused in
for-profit areas. All patients should receive equal quality and commission of essential
health care. Affordable options such as using cellophane and waterproof tape may be
viable solutions to overcoming the expense of using brand name medical products
without reducing care quality. In addition, like dressings, some patients may not tolerate
adhesive shower coverings and securement devices. Topical skin barriers and/or
hydrocolloid dressings in conjunction with adhesive should be used with discretion over
removing the dressing entirely.
It appears the recent trend to remove the dressing from a healed tunneled exit site
is not only a safe strategy it is also a cost-effective alternative to using a gauze dressing in
terms of supply charges. In accordance with asepsis theory, the embedded cuff suffices
as a barrier while removing the dressing maintains a dry environment. Daily skin
cleansing with the no dressing strategy also ensures more frequent attempts to reduce
microbial load around the exit site. However, daily skin antisepsis after showering as
opposed to cleansing once per week incurs fees for supplies that exceed the more
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traditional approach of using a transparent dressing. Options at the bedside should
consider additional potential factors that inflate expenses when treatment is lengthy.
A recent survey of Canadian CVC practice in blood stem cell transplant reports
registered nurses spend up to 30 minutes for a single dressing change with average time
of 15 minutes (Keeler, 2014). A review of collective agreements for nursing wages in
Canada in 2013 (Table 10), reveals that the national average hourly wage for a level I
registered nurse (excluding the Territories and Quebec) is $35.28. The gauze dressing
strategy incurs more than double the expense of a transparent dressing when considering
nursing wages that do not need to be factored into the costs of the no dressing strategy.
Removing the dressing from a healed tunneled CVC site can reduce time constraints on
registered nurses that perform dressing change procedures and educate others so the task
can be delegated.
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Increment BC
1
30.79
2
31.96
3
33.16
4
34.33
5
35.52
6
36.71
7
37.90
8
39.02
9
40.42
Average
31.04
National Average

Table 10
Average Canadian 2013 Registered Nursing Wages
AB
SK
MB
ON
NB
NS
35.00 34.94 31.02 30.17 29.86 32.84
36.34 36.59 32.10 30.91 31.87 33.82
37.69 37.43 33.19 31.12 33.05 34.91
39.04 38.28 34.32 32.65 34.42 36.13
40.39 39.19 35.428 34.2
35.76 37.39
41.72 40.09 36.572 36.12 36.80 38.69
43.08 41.45
38.06 37.88
44.35 42.81
40.01
45.93 44.08
42.85
40.39 39.43 33.77 35.94 34.23 35.63

PEI
29.57
30.77
32.16
33.53
34.91
36.03
32.82

NFLD
30.77
31.98
33.28
34.88
36.46
38.10
34.25
35.28

*Excluding QC and the Territories
* For level I registered nurses excluding education/shift/weekend/long-service differentials, or retrospective lump sum payments

Patient context may be the most important factor in determining the type of CVC
exit site care required. Typically, individuals with allergies to adhesive employ the use of
a gauze dressing. Dressing removal may also serve as a more comfortable option to other
individuals by eliminating pruritus and decreasing excoriation from repeat adhesive
removal. Findings from this study suggest that resorting to no dressing is a more costeffective approach than using gauze. Dressing removal may also relieve care burden on
patients and lay caregivers by simplifying the amount of education needed and
minimizing the number of tasks required for self-care. Cost savings should be balanced
with patient preference and provider experience when implementing nursing policy.
It was noted that adherence to the policy of removing the dressing was not rapidly
incorporated at the study site. Clinical documentation indicated some patients were
anxious and/or uncomfortable leaving the exit site open to air. Non-adherence to
removing the dressing after the policy change could have result-limiting effects.
Individuals who refused the no-dressing strategy were eligible to be included in the
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sample. It is unclear if individual choice increases vigilance with infection prevention;
however, results do not indicate significant infection reduction in groups that used
dressings.
Conclusion
The decision to dress and maintain a CVC dressing is the responsibility of
clinicians who employ best practices based on empirical evidence, clinical expertise, and
patient preference. Differences in nursing care strategies are not necessarily disparities.
Rather the various care approaches may represent conscious efforts of nurses applying
theoretical and practice-based experience at the bedside. The study empirically supports
each dressing strategy in terms of infection risk while weighing in on certain costs and
benefits. Overall, this study supports the traditional use of transparent dressings on a
tunneled CVC in the blood stem cell transplant population unless circumstances dictate
intolerance. The no dressing strategy is the recommended alternative to a transparent
dressing as it is a safe and more cost-effective approach than using gauze dressings.
Further cost containment can be achieved with the no dressing strategy by reducing time
constraints on nurses and patients that are difficult to quantify in monetary measures.
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Chapter Five: Summary
Registered nursing is a theoretically based science that involves application of
experience, skills, and evidence-based interventions. Nurses are not as interchangeable
between practice settings as their historic counterparts. Specialty areas require
competencies that were once viewed as advanced practice. The evolution of healthcare
has pushed nursing research to examine specific gaps in evidence within specific
populations and specific circumstances. This research approach not only assists in
controlling construct validity; it also fine tunes nursing science and confirms theoretical
standpoints for care strategies that have not been empirically tested.
Blood and marrow cell transplant nursing is a unique practice specialty with its
own nursing subculture. Nurses in this area have first-hand familiarity with common
morbidities associated with cancer treatment. Leung et al. (2012), report that bone
marrow transplant nurses in Canada undergo immense stress when they know their
patients are suffering. The interpersonal element of care gives rise to leadership and
advocacy at the bedside that can be critical to patient well-being. When nursing practice
changes are imposed with little support, the professionals expected to deliver care may
question quality measures. In turn, administrators may be faced with lack of adherence to
policy. Légaré et al. (2010) also point out the importance of shared decision-making that
maintains the patient as the centre focus and incorporates family and significant others.
The model includes the client as a key stakeholder in inter-professional collaboration and
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mitigates barriers to the most appropriate plan of care for an individual. It is essential
that policy decisions include input from frontline personnel and be communicated with
credible evidence to achieve a buy in for change; especially when the ramifications for
practice are life threatening and expensive. Building organizational rapport may also
indirectly influence bedside rapport and patient satisfaction with care recommendations.
The general topic addressed by this research project involved clinical changes to
CVC care practice with blood and marrow cell transplant recipients. Guiding evidence to
support these actions was conflicting and/or absent in the literature. It was first
established through a descriptive survey that CVC practice differs across Canada;
however, the individual needs of each patient were considered to be a primary
consideration when selecting an exit site care strategy for a tunneled CVC. Other
discrepancies such as different competency training approaches and flushing protocols
are worth future nursing research attention. Blanketing strategies across the entire blood
stem cell transplant population undermines the flexibility and judgment of unique
circumstances in registered nursing. Differences in care do not constitute disparity;
rather, they provide options that require expertise for selection.
Awareness of the cost implications for nursing care strategies may assist the
organization in capital planning. The study estimating the cost of CRBSI in blood and
marrow cell transplant recipients with a tunneled triple lumen subclavian CVC was
conducted with the intent to highlight the importance of infection prevention. Findings
revealed significant healthcare expenses in the presence of CRBSI within the blood stem
cell transplant population which are higher than infection costs in other clinical areas.
Budgets should not dictate clinical decisions that favor administrative goals over patient
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outcomes. Abuse of this knowledge has the potential to violate the trust of both
consumers and clinicians alike. Insights into the costs of negative outcomes should be
used for targeting prevention strategies that maintain patient-focused quality care. In
turn, solutions can serve multifaceted purposes that meet the goals of all parties involved
in the healthcare system.
The third study compared the no-dressing strategy that was the subject of a
practice change initiated at a large transplant center in Canada to two other dressing
alternatives for patients with tunneled catheters who received blood stem cell transplant.
Findings were able to substantiate all three care approaches in terms of infection risks.
Results fill the gap in the evidence for recommending removing the dressing from a
healed tunneled CVC exit site. Analysis of the costs and benefits of each strategy may
further inform practice decisions at bedside and administrative levels. Nursing care of
the exit site did not positively influence infection outcomes provided all other current
guidelines are followed. Additional research investigation of other areas of nursing
influence may further elucidate unknown sources of CRBSI.
Findings from all three studies have the potential to influence stem cell nursing
practice in Canada and across the globe. Further analysis of the large data set generated
in this project is planned to delineate other areas of nursing influence on long-term
tunneled triple lumen subclavian CVC-related complications. Specific attention will be
given to other complications noted in data collection such as occlusion and thrombosis in
the superior vena cava, accidental line removal, and tunnel infection. A more
comprehensive analysis of specific organisms and gram staining will also be considered.
Future research efforts will continue to focus on generating evidence to support practice
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decisions for care of patients receiving stem cell transplants for hematologic disorders
and malignancies.

70

References
Légaré., F., Stacey, D., Gagnon, S., Dunn, S., Pluye, P., Frosch, D., . . . Graham, I.D.
(2010). Validating a conceptual model for an inter-professional approach to
shared decision making: A mixed methods study. Journal of Evaluation in
Clinical Practice, 17,554-564.
Leung, D., Fillion, L., Duval, S., Brown, H., Rodin, G., & Howell, D. (2012). Meaning
in bone marrow transplant nurses’ work: Experiences before and after a
“meaning-centered” intervention. Cancer Nursing, 35(5), 374-381.
Majid, S., Goo, s., Luyt, B., Zhang, X., Theng, Y-L., Chang, Y-K., & Mokhtar, I. (2011).
Adopting evidence-based practice in clinical decision making: nurses’
perceptions, knowledge, and barriers. Journal of the Medical Library
Association, 99(3), 229-236.
Weissinger, F., Auner, W., Bertz, H, Buchheidt, D., Cornely, O.A., Egerer, G., . . . Wolf,
H.H. (2011). Antimicrobial therapy of febrile complications after high-dose
chemotherapy and autologous hematopoietic stem cell transplantation-guidelines
of the Infectious Diseases Working Party (AGIHO) of the German society of
Hematology and Oncology (DGHO). Annals of Hematology,91,1161-1174.
Westbrook, J.L., Duffield, C., Li, L., & Creswick. (2011). How much time do nurses
have for patients? A longitudinal study quantifying hospital nurses’ patterns of
task time distribution and interactions with health professionals. BioMed Central
Health Services Research, 11(319), 2-12.

71

Appendix A
Survey
Cover Letter
Dear Participant
Due to your experience, you have been selected to participate in a research study on
central venous catheter practice in Canadian cell transplant. Your perspective will help
inform health policy and future research. This study is being conducted by a Canadian
doctoral candidate studying at the University of Texas at Tyler.
A link to an attached survey is provided at the end of this document. Participation
assumes your consent. You will receive an e-mail reminder of the survey if you are
unable to participate at this time. Results of your survey will be compared to other
Canadian transplant centres. The information you provide will be summarized and
reported within a nursing doctoral dissertation and potentially a peer reviewed academic
journal.
You are free to ask questions or discuss participation at any time. You are also free to
withdraw at any time without prejudice. Participants will be entered to win a random
draw for a $50 Tim Horton’s gift card. For information or questions feel free to contact
Melanie Keeler at (403) 890-9249 or mkeeler@patriots.uttyler.edu
This study has been approved by the Institutional Review Board at the University of
Texas at Tyler.
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Survey Questions
Demographic Questions
1. In what Canadian Province or territory is your centre located?
YT NT NU BC AB SK MB ON QC NB NS NL PEI
2. Does your centre provide any of the following transplants (check all that apply)
blood cell
bone marrow
cord
hematopoietic progenitor stem cell

3. What is the estimated number of transplant patients treated at your centre each
year?
50 or less

50 to 100

more than 100

4. Is your centre considered
A) Adult
B) Pediatric
C) Both
Content Questions
The following section concerns central line education
5. Does your centre have a policy in place to educate clinicians about central lines?
Insertion
Routine Care
Maintenance

Yes
Yes
Yes

No
No
No
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6. Does your centre have a policy in place to educate patients, family, or lay
caregivers about central lines?
Routine Care
Maintenance Yes

Yes
No

No

7. How often is education on central line care reinforced at your centre for example,
recertification, lunch and learn, or training modules?
Never

Yearly

Other______

The following section concerns the insertion of central lines at your centre
8. Who is responsible for inserting central lines (excluding PICCS) at your centre?
Radiologist/Radiology Resident
Physician/Resident Physician
Anesthesiologist
Specialty Nurse
Other (specify)_____
9. Where are non-emergent central lines inserted at your centre?
Bedside
Radiology department
Operating room
Angio suite
Other (specify)_____
10. Select the barrier precautions used at your centre for central line insertion?
(Check all that apply)
Hand washing
Sterile field/drape/gown
Aseptic technique
Antiseptic skin preparation
Mask
Sterile glove
Clean glove
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11. What type of antiseptic solution is used for central line insertion at your centre?
Unknown
0.5% chlorhexidine
2% chlorhexidine
Tincture of Iodine
Iodophor
70% Alcohol
Other (specify)_____

12. What type of central line is preferred and/or most commonly used for cell
transplant recipients at your centre?
Tunneled
Non-tunneled
Port/IVAD
IJ
Femoral
PICC
Other (specify)_____
13. Does your centre use ultrasound guidance for central line insertion (excluding
PICC)?
Always

When possible

Never

Unknown

14. How many lumens do the majority of central lines have in cell transplant
recipients at your centre?
1
2
3
More than 3
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15. Does your centre use central lines impregnated with antimicrobial agents?
Yes Line
Yes cuff and line
No
Unknown
16. Do cell transplant recipients at your centre receive prophylactic antibiotics prior
to line insertion?
Yes
No
Unknown
17. Is there a preferred insertion site for central line catheters in cell transplant
recipients at your centre?
Physician preference
No
Right subclavian
Left subclavian
Right IJ
Left IJ
Right Port/IVAD
Left Port/IVAD
Double lumen Port/IVAD
Right Femoral
Left Femoral
Right PICC
Left PICC
The following section concerns central line maintenance at your centre
18. What solution is used with central line catheters (excluding PICCS) at your
centre?
Not applicable
Flushing solution______
Locking solution______

Volume (mL)______
Volume (mL)______
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19. Does your centre instill any of the following solutions into the lumen of an
infected central line or when a central line infection is suspected? (check all that
apply)
No
Sodium citrate
Ethyl Alcohol
Vancomycin
Gentamyacin
Other (specify)_____
20. Does your centre use any solutions with occluded or suspected central line
occlusion?
No
High dose heparin (5000u/mL or >)
Alteplase/Tpa
Other (specify)_____
The following section concerns central line care at your centre
21. What type of dressing is applied to a central line at your centre immediately after
insertion?
Pressure
Gauze
Gauze and transparent
Mepore/Premapore
Other (specify)_____
22. At what point after insertion is the initial dressing changed for a central venous
catheter (excluding PICC)?
24 hours or earlier if soiled
48 hours
1 week
Other (specify)_____
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23. What type of dressing is most commonly applied to a central line when the initial
dressing is removed?
Gauze (with or without disc)
Semi-transparent film such as tegaderm
Mepore/Primapore
Biopatch or chlorhexidine sponge
Other (specify)___
24. How often is a non-soiled central line dressing changed at your centre?
Daily
Every 48 hours
Weekly
No more than once every 7 days
Other (specify)_____
25. What is the average amount of time spent by you or a staff member for one
central line dressing change?
<15 minutes
more

15-30 minutes

30-45 minutes

45 minutes or

26. Does your centre maintain a dressing on a healed tunneled central line exit site?
Yes

No

27. Who performs central line dressing changes at your centre? (check all that apply)
Physician
Nurse Practitioner/Clinical Nurse Specialist
Registered Nurse
Licensed Practical Nurse
Patient
Family Member
Lay caregiver
Other (specify)_____
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28. What barriers/ precautions are used at your centre for central line dressings by
staff at your centre? (check all that apply)
Mask
Sterile gown
Sterile gloves
Clean gloves
Sterile drape
0.5% chlorhexidine
2% chlorhexidine
Iodaphor
Tincture of iodine
70% alcohol
Alcohol swabs
Normal saline
Other (specify)_____
29. At your centre, do cell transplant recipients with central lines use additional
barriers or coverings such as aquaguard while showering?
No
Yes at all times and with all dressing types
For gauze dressings only
For healed tunneled lines open to air only
Other (specify)
30. How often is exit site skin care performed on central lines that do NOT have a
dressing?
Not applicable
Daily
More than once a day
Only after showering
Other (specify)
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The following section deals with central line removal at your centre
31. Who is responsible for removing central lines (excluding PICC) at your centre?
Anesthesiologist
Physician/Resident physician
Advanced practice nurse
Registered Nurse
Anyone trained in the procedure
Other (specify)______
32. Are central lines in cell transplant recipients promptly removed at your centre
when no longer essential?
Yes

No

33. Under what circumstances would a cell transplant recipient have a central line
replaced at your centre? (check all that apply)
Suspect infection
Known infection
Suspect occlusion/thrombus
Known occlusion/thrombus
Malfunction
Other (specify)_____
Thank you for your time and participation. If you wish to be informed of the survey
results please provide your contact information and preferred method of communication.
This information will be stored in confidence and securely destroyed after results have
been shared with you.
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Appendix B
Institutional Review Board Approvals
The University of Texas at Tyler
Institutional Review Board
October 10, 2013
Dear Ms Keeler,
Your request to conduct the study: Cost-benefit Analysis of Tunneled Central Venous
Catheter Dressings in Canadian Stem Cell Transplant Recipients IRB #F2013-17 has
been approved by The University of Texas at Tyler Institutional Review Board under
expedited review. This approval includes a waiver of written informed consent, and
is conditional on approval by the Alberta Cancer Research Ethics Committee. In
addition, please ensure that any research assistants are knowledgeable about
research ethics and confidentiality, and any co-investigators have completed human
protection training within the past three years, and have forwarded their
certificates to the IRB office (G. Duke).
Please review the UT Tyler IRB Principal Investigator Responsibilities, and
acknowledge your understanding of these responsibilities and the following
through return of this email to the IRB Chair within one week after receipt of
this approval letter:






This approval is for one year, as of the date of the approval letter
Request for Continuing Review must be completed for projects extending
past one year
Prompt reporting to the UT Tyler IRB of any proposed changes to this
research activity
Prompt reporting to the UT Tyler IRB and academic department
administration will be done of any unanticipated problems involving
risks to subjects or others
Suspension or termination of approval may be done if there is evidence of
any serious or continuing noncompliance with Federal Regulations or any
aberrations in original proposal.
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Any change in proposal procedures must be promptly reported to the IRB
prior to implementing any changes except when necessary to eliminate
apparent immediate hazards to the subject.

Best of luck in your research, and do not hesitate to contact me if you need any
further assistance.
Sincerely,

Gloria Duke, PhD, RN
Chair, UT Tyler IRB
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30 October 2013

Dear
Re:

26162: Cost-benefit Analysis of Tunneled Central Venous
Catheter Dressings in Canadian Stem Cell Transplant Recipients

Thank you for submitting the proposal for the above named study. On behalf of the
I have reviewed the following
documents as of 18
October 2013:



Application for Research of Minimal Risk dated 11 October (received 16
October 2013)
The University of Texas at Tyler Institutional Review Board
Approval Letter and Application dated 10 October 2013

Thank you also for your submission dated 25 October 2013 in response
to correspondence dated 21 October 2013, together with the following:


Application for Research of Minimal Risk dated 25 October (received 25

October 2013) As of 28 October 2013, the following documents have been
approved:


Application for Research of Minimal Risk dated 25 October (received 25
October 2013)
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Please note that this approval is based on the following conditions:
if there are any other changes to the protocol during the year, a letter
describing the changes must be forwarded to the
 an Annual Renewal form must be submitted two months prior to the
deadline date of 18 October 2014 (one year from the date of initial
 review) containing the information as per our annual renewal form;
 a Final Report must be submitted at the termination of the project.

The deliberations of the
include all elements described in Section 50 of
the Health Information Act, and this study was found to be in compliance with all
the applicable requirements of the Act. Access to personal identifiable health
information was requested in this ethics application, however upon review, the
has waived consent as it was demonstrated to
be impractical, unreasonable or not feasible to obtain.
The
guidelines and regulations:








complies with the following

Tri-Council Policy Statement: Ethical Conduct for Research Involving
Humans;
Health Information Act which has been proclaimed on April 25, 2001 in
Health Canada, as defined in C.05 (Part C Division 5) (1024 - Clinical
Trials) of the Food And Drug Regulations -Amendment and the
Therapeutic Products Directorate Guidelines /ICH Harmonized Tripartite
Guidelines - Good Clinical Practice: Consolidate Guidelines;
National Institutes of Health - Code of Federal Regulations (USA); and
Our institution has been approved by the Office for Human Research
Protections in the United States.

Members of the
who are named as investigators or co/sub-investigators in
research studies do not participate in discussion related to, nor vote on, such
studies when they are presented to the
.
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Please accept the Committee’s best wishes for success in your

research. Sincerely,

Associate Chair,
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The University of Texas at Tyler
Institutional Review Board

October 10, 2013

Dear Ms Keeler,

Your request to conduct the study: Cost-benefit Analysis of Tunneled Central Venous
Catheter Dressings in Canadian Stem Cell Transplant Recipients IRB #F2013-17 has
been approved by The University of Texas at Tyler Institutional Review Board under
expedited review. This approval includes a waiver of written informed consent, and is
conditional on approval by the Alberta Cancer Research Ethics Committee. In addition,
please ensure that any research assistants are knowledgeable about research ethics and
confidentiality, and any co-investigators have completed human protection training
within the past three years, and have forwarded their certificates to the IRB office (G.
Duke).
Please review the UT Tyler IRB Principal Investigator Responsibilities, and
acknowledge your understanding of these responsibilities and the following through
return of this email to the IRB Chair within one week after receipt of this approval
letter:





This approval is for one year, as of the date of the approval letter
Request for Continuing Review must be completed for projects extending past
one year
Prompt reporting to the UT Tyler IRB of any proposed changes to this research
activity
Prompt reporting to the UT Tyler IRB and academic department
administration will be done of any unanticipated problems involving risks to
subjects or others
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Suspension or termination of approval may be done if there is evidence of any
serious or continuing noncompliance with Federal Regulations or any aberrations
in original proposal.
Any change in proposal procedures must be promptly reported to the IRB prior to
implementing any changes except when necessary to eliminate apparent
immediate hazards to the subject.

Best of luck in your research, and do not hesitate to contact me if you need any further
assistance.
Sincerely,

Gloria Duke, PhD, RN
Chair, UT Tyler IR
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Guidelines for Authors
Introduction
The Canadian Oncology Nursing Journal (CONJ) welcomes original articles,
research papers, letters to the editor, media reviews, professional ads, and stories of
interest to nurses who provide care to patients with cancer and their families.
Policy
All correspondence and manuscripts must be forwarded to the editor-in-chief. The
editor-in-chief or delegated associate editors will assume responsibility for obtaining
confidential peer review. Normally, the process of peer review takes approximately
three months. If published, manuscripts become the property of CONJ. The journal
will have exclusive rights to the manuscript and to its reproduction. Manuscripts
may not be under consideration by any other journal.
Copyright
When submitting a manuscript, include a statement of ownership and assignment of
copyright as follows: "I hereby declare that I am the sole proprietor of all rights to
my original article entitled…, and I assign all rights to CANO/ACIO for publication
in the Canadian Oncology Nursing Journal." Please date and sign. ALL authors must
sign this statement. Please submit this statement in a WORD document by electronic
mail to the editor in chief, CONJ.
Authors must obtain written permission for use of previously published materials
included in the manuscript. This includes extensive quotations (greater than 500
words), tables, figures, charts, graphs, etc. Written permission for all copyright
materials must be included with the manuscript.
Manuscript Content
1. Style
Manuscripts must be typewritten or word processed in times roman or courier
typeface using a 12 points font. Copy must be clear and legible. Uniform margins of
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at least 1 inch, and double spacing are required. Number pages consecutively in
upper right-hand corner, beginning with title page. Identify each page with the first
two or three words from the title inserted above the pagination. Use one side of the
paper only. The required style is that recommended by the American Psychological
Association (APA). (2001). Publication manual (5th ed.). Washington, DC: Author.
2. Length

The preferred length is 6 to 16 double-spaced pages including tables, figures, and
references.
3. Title page
The title page must include the title of the article, the name(s) of the author(s) as
meant to appear in the publication, and, if possible, an e-mail address where the main
or contact author may be reached. If more than one author, the order must be that
desired in the publication. Accuracy is essential to ensure accuracy in publication.
Include the author(s) credentials, position, place of employment, correct mailing
address, telephone and facsimile numbers. Indicate preferred author and address for
correspondence.

1.
Abstract
Include an abstract of 100-120 words. This abstract should summarize the article and
highlight the main points of interest for the reader. It must be double-spaced and on a
separate page.
2.
References
References must be double-spaced, in alphabetical order, complete, and accurate.
References should start on a separate page and must be cited in the text.
3.
Tables
Tables are numbered consecutively in the order in which they are first mentioned in the
text. Double-space and begin each table on a separate page. Tables should complement,
not duplicate text.
4.
Figures
All figures must be copyrighted and documented. They must be submitted on separate
pages and should not duplicate text. Number consecutively in the order in which they are
first mentioned in the text. Figures must be clear, easy to interpret, and in black and
white only for reproduction.
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5.

On acceptance for publication

Manuscripts accepted for publication are subject to copyediting. Electronic copies should
be on the Windows operating system and rich text format is preferred.
Correspondence
A letter of query to the editor-in-chief regarding suitability of a proposed manuscript is
suggested, but not required. Forward the original complete manuscript in a WORD
document by electronic mail to the editor-in-chief. Include your e-mail address and other
contact addresses with your manuscript for acknowledgement of receipt of your
manuscript.
Non-refereed material
The journal also invites brief submissions of less than 500 words that highlight clinical
practice tips, new program developments, research in progress, or reviews of articles,
books, and videotapes. These submissions are published at the discretion of the editor-inchief. Queries are unnecessary.
Language
Articles will be published in the language of submission with a summary in the other
official language (French or English). Selected articles will be translated in total. The
Canadian Oncology Nursing Journal is officially a bilingual publication.
Heather Porter, RN, Ph.D. hbporter@rogers.com Editor-in-Chief
Canadian Oncology Nursing Journal (CONJ) 14-54 Blue Springs Drive
Waterloo, ON N2J 4M4 Tel: (519) 886-8590
Fax: (519) 886-9329
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Permission Letter
2/17/2014
Melanie Keeler
1047 Maggie Street, SE Calgary, AB
T2G4L8 Canadian Oncology Nursing
Journal
375 West 5th Avenue, Suite 201, Vancouver BC, V5Y 1J6
Dear Dr. M. Fitch:
I am preparing my dissertation at The University of Texas at Tyler, with plans to
co1nplete my degree on May 9, 2014. We use a multi-paper format for our
dissertation portfolio, which includes papers we have written and/or published.
The article Central Line Practice in Canadian Blood and Marrow Cell Transplant,
of which I am first author, is scheduled to appear in your Canadian Oncology
Nursing Journal, reports an essential part of my dissertation research. I would like
permission to reprint the article as a chapter in my dissertation portfolio. As per
your preference, I can either include a pdf of the published article or a word
document of the submitted article with reference to the journal.
Following the final dissertation defense, our dissertation portfolios are submitted
to our institutional repository and access may be restricted to those currently
employed or enrolled at The University of Texas at Tyler. The copyright for the
article named above remains with the Canadian Oncology Nursing Journal.
Submission to our institutional repository will in no way restrict republication of
the material in any other form by you or by others authorized by you
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If you have any questions, please contact me at mkeeler@patriots.uttyler.edu or
my dissertation chair, Dr. B. Haas at bhaas@uttyler.edu. Thank you for your
assistance,

x
Melanie Keeler
RN, PhD candidate a t the University of Texas
I hereby give permission for the use as requested above:
x
Marg Fitch
Editor In Chief CONJ
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Personal Statement

The goal of the proposed research was to investigate Canadian blood and marrow cell
transplant nursing practice with central venous catheters in terms of cost. Specifically,
we measured differences in catheter-related bloodstream infection across six-year period
in a cohort of adult blood and marrow transplant recipients with long-term tunneled triple
lumen subclavian central venous catheters that used different types of dressings
(transparent, no dressing, or gauze). Concomitant analysis of the cost of infection and
cost of each dressing strategy was conducted. My clinical background in hem-oncology
nursing and post-graduate coursework in nursing and research enabled me to successfully
carry out the study.
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